In a troubling policy shift, Blue Cross Blue Shield is now forcing patients like 12-year-old Madison to self-administer Xolair injections at home instead of receiving them in-clinic. This change raises serious safety concerns due to potential risks like anaphylaxis during self-injection. Advocates worry that this will not only affect asthma medications but could set a precedent for other insurers to follow suit, potentially limiting access to essential drugs in pursuit of profits. Patient safety and access to medical support are at stake as insurers prioritize cost-cutting measures.
"I don't think I would want to do the shot at all. I don't know if I would be comfortable even doing it."
Collection
[
|
...
]